Max Robotics — Global Service Robot Directory + US Certification

About

Thomas Lam is a leading urological surgeon and researcher whose work has fundamentally shaped the evidence base for managing urological cancers. His primary research areas encompass the surgical and ablative treatment of renal and prostate cancers, with a particular focus on perioperative outcomes, oncological efficacy, and quality of life. Lam’s major contributions are anchored in high-impact systematic reviews and meta-analyses that have directly informed clinical guidelines. His seminal 2012 work on perioperative and quality-of-life outcomes following surgery for localised renal cancer (288 citations) remains a cornerstone in the field. He further advanced the standard of care with a pivotal European Association of Urology guidelines review comparing laparoscopic versus open nephroureterectomy for upper tract urothelial carcinoma (156 citations). More recently, Lam has critically evaluated the emerging role of focal ablative therapy for prostate cancer, highlighting its limitations versus standard management. He is also a key contributor to the RECUR database, providing crucial insights into recurrence patterns in renal cell carcinoma. Through his rigorous, guideline-shaping work, Lam has become an indispensable voice in evidence-based urological oncology.